STA Research assigns a Speculative Buy on Tetra Bio Pharma Inc, with a 20 cent target forecast on the stock price.
Based on the Tetra Bio Pharma Inc stock (tbp stock price) forecasts from 1 analysts, the average analyst target price for Tetra Bio Pharma Inc (tbp stock price) is $0.20 over the next 12 months. Tetra Bio Pharma Inc’s average analyst rating is Speculative . Stock Target Advisor’s own stock analysis of Tetra Bio Pharma Inc (tbp stock price) is Bearish, which is based on 1 positive signal and 6 negative signals. At the last closing, Tetra Bio Pharma Inc’s stock price was CAD 0.06. Tetra Bio Pharma Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -84.06% over the last year.
Tetra Bio-Pharma Inc. is a biopharmaceutical firm that is involved in the research and development of cannabinoid-derived medicines for oncology, ophthalmology, inflammation, and pain. The corporation has its headquarters in Canada’s Orléans.
What we like:
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What we don’t like:
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector